Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melamine In U.S. Could Pose More Risk To Food Safety Regime Than Infants

This article was originally published in The Tan Sheet

Executive Summary

FDA says trace amounts of melamine found in U.S.-manufactured infant formula poses no danger, but the discovery will likely lead to a renewed push for food safety oversight and possibly for a separate food safety agency

You may also be interested in...



FDA Finds Morphine-Spiked Herbal Cough Syrup In Chinese Firm's Plant

The finding of morphine in a consumer health product made in China could rekindle concerns about lapses in supply chain security previously linked to drugs and adulterants or contaminants found in other imported FDA-regulated products.

China Leads Emerging Markets Poised For Strong Nutrients Sales Growth

Global sales of nutrients, herbals, minerals and vitamins should reach $23.7 billion by 2015, according to the Freedonia Group. Firms seeking to cash in on this growth should consider China, where sales will surpass the U.S. by 2020, making it the largest national market for nutraceuticals.

China Leads Emerging Markets Poised For Strong Nutrients Sales Growth

Global sales of nutrients, herbals, minerals and vitamins should reach $23.7 billion by 2015, according to the Freedonia Group. Firms seeking to cash in on this growth should consider China, where sales will surpass the U.S. by 2020, making it the largest national market for nutraceuticals.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel